All Psychedelic News

This page displays all news posts in Blossom’s database in one list.

To use all the search functionalities available on Blossom, see our Latest News Search page.

Or navigate to one of our other databases | Courses Search (List) | Books Search (List) | People Search (List) | Companies Search (List) | Papers Search (List) | Videos Search (List) | Measures Search (List) | Trials Search (List) | Events Search (List) | Compounds Overview (List) | Topics Overview (List) | Countries Overview (List)

All Psychedelic News on Blossom List

• atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
• Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
• First-of-its-kind MDMA group therapy trial set to commence
• Congressional Leaders Urge Psychedelics Research For PTSD And Depression In Updated Spending Measures
• Federal Health Officials Say Psychedelics’ Illegal Status Makes It Harder For Researchers To Study Them
• Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration
• A Psychedelic Renaissance at the V.A.
• Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
• Enosis Therapeutics Generates Positive Results from World’s First Study of the Synergistic Application of Virtual Reality and Psychedelics
• U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
• Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression
• Launch of the Psychedelic Access and Research European Alliance – PAREA
• Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
• How psychedelic drugs might treat depression
• Let doctors use MDMA to treat veterans with PTSD and depression, former ADF boss says
• Tripp Raises Another $11 Million; Unity CEO’s Metaverse Messaging
• Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
• Awakn Life Sciences Initiates Follow-on Behavioral Study to Focus on Gambling Disorder
• Ehave Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research
• Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Methods of Administering Psilocybin and Psilocin
• Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
• Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health
• ‘We spark curiosity’: how the psychedelics industry is taking on Davos
• Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101
• Ceruvia Lifesciences Submits FDA Investigational New Drug Application for Psilocybin Obsessive-Compulsive Disorder Program
• Clerkenwell Health Taps Top Academics and Expands Pan-European Scientific Advisory Board
• Oregon Psilocybin – Administrative Rules
• Psychedelics In Davos? Jason Silva Explains What’s Happening During The World Economic Forum
• $2.7M Grant to UC Davis to Find New Addiction Treatments Related to Psychedelics
• COMPASS Pathways presents the largest ever study of psilocybin therapy, at the American Psychiatric Association annual meeting
• THE FIRST-EVER MEDICAL PSYCHEDELICS SERIES AT DAVOS 2022 hosted by Energia Holdings Incorporated
• MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
• Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction
• CSIRO starts work on medicinal psychedelics
• Inside the Dispute Over a High-Profile Psychedelic Study
• Albert Labs secures psilocybin licence from Health Canada
• Awakn Life Sciences Appoints Uk Leader In Addictions Psychiatry, Dr. Arun Dhandayudham, As Chief Medical Officer
• Zylorion Receives Approval for Phase II Clinical Study for its Proprietary Almond Therapy
• Beckley Retreats offers science-backed psychedelic experiences
• OSU launches centre to study therapeutic potential of psychedelics
• MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
• Psychedelic Patents are Broken Because the Patent System Is Broken
• Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets
• COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
• Magic psilocybin truffle study targets war veterans exclusively – finds salient reductions in PTSD, anxiety & depression up to 8 weeks
• Europe’s first psychedelic drug trial firm to open in London
• Psychedelics startups are on a long journey to consumer markets, but these 5 VCs are taking the ride
• COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
• Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies
• TRYP Therapeutics Doses First Patients in Phase 2 Psilocybin Trial
• Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility
• Lessons Learned At The Benzinga 2022 Psychedelics And Cannabis Capital Conferences
• Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products
• COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers
• Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
• Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
• Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
• A psychedelic therapist allegedly took millions from a Holocaust survivor, highlighting worries about elders taking hallucinogens
• Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT
• Five governments around the world are now funding psychedelics research
• Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder
• ‘Magic mushrooms’ for therapy? Vets help sway conservatives
• Massachusetts Psychedelics Activists Plan To Put Decriminalization On Local Ballot And Force Lawmakers To File State Bills
• Freedom to Operate Releases Study to Protect the Development of LSD-based Therapies from Unfounded Patent Claims
• Magic Mushrooms Are Giving Investors a Bad Trip
• Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
• Filament Healht Issued Patent By United States Patent and Trademark Office
• Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds
• New Evidence That Psilocybin May ‘Rewire’ Brain To Help Those With Depression
• Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
• Health Canada announces review of all MDMA trials, as complaint alleges major flaws and safety issues
• Homecoming Closes $4 Million Seed Funding Round To Scale Psychedelic Therapy Companion Tools
• Awakn Successfully Completes Phase One Of Its Drug Discovery Program
• Psychedelic Pharmaceutical Startup Ninnion Announces Patent Filings and Development of NIN-S119 for Ischemic Stroke
• Colorado Lawmakers Approve MDMA Bill While Rejecting Broader Psychedelics Measure As Ballot Initiatives Loom
• Health Canada Approves First Special Access Request for Psilocybin
• MAPS Canada announces its new partnership with the groundbreaking non-profit Roots To Thrive
• Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
• The Next Big Addiction Treatment
• Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
• Novamind Partner to Acquire Specialized Ibogaine Group in Brazil
• Eleusis Announces Notice of Allowance for US Patent Application With Claims Covering Lead Drug Candidate ELE-Psilo
• NeonMind Announces Positive Preclinical Results Demonstrating the Efficacy of Psilocybin in Reducing Weight Gain in Obese Animal Subjects
• Georgia Lawmakers Approve Bill To Create Psychedelic Study Committee
• Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
• Gilgamesh Announces Clinical Candidates For Two Programs With First In Human Dosing to Begin in Late 2022
• You May Soon Find Mental Health Help From Psychedelic Drug-Assisted Psychotherapy In The Metaverse
• Awakn CEO on Addiction: ‘The Biggest Unmet Medical Need of Modern Times’
• Can magic mushrooms be used to treat racial trauma?
• Utah Governor Signs Bill To Study Use Of Psychedelics For Mental Health Therapy
• Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida
• Filament Health Announces Second Patent Issuance
• Awakn Life Sciences Announces Closing of Private Placement
• New partnership launched with SLaM and COMPASS Pathways
• Engineering to neuroscience: Meditation, psychedelics, and unlocking the mysteries of the brain
• NeonMind Files Provisional Patent Application For Psilocybin Induced Weight Loss
• Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
• PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
• Another Psychedelics Company Is Crashing
• Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT
• Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
• Concert tunes pipeline by selling off CNS assets to startup Terran Biosciences
• Demand for This Toad’s Psychedelic Venom Is Booming. Some Warn That’s Bad for the Toad.
• Connecticut Lawmakers Approve Bill To Fund Psilocybin And MDMA Therapy
• Can Psychedelics like MDMA Cure Eating Disorders?
• Psilocybin Is The Most Studied Psychedelic
• California Activists Drop 2022 Psilocybin Legalization Ballot Initiative After Falling Short Of Signature Requirement
• Largest ever psychedelics study maps changes of conscious awareness to neurotransmitter system
• Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
• Mind Cure Health Halts All Psychedelic Business Activity
• Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013
• Connecticut Lawmakers Discuss Bill To Fund Psilocybin And MDMA Therapy
• Oregon’s psychedelic mushroom regulators accused of conflict of interest
• Washington State Legislature Approves $200,000 In Psilocybin Research Funding In Budget
• Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin
• Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
• Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research
• A Precautionary Approach to Touch in Psychedelic-Assisted Therapy
• Johns Hopkins, Yale, and NYU are teaming up to tackle a key bottleneck that will arise as psychedelics come to market
• ‘It’s not medical’: Oregon wrestles with how to offer psychedelics outside the health care system
• Former Moderna Vice President Joins Psychedelics Company In Phase 3 Trials For Ecstasy
• Hawaii Senate Unanimously Approves Psilocybin Task Force Bill, With Decriminalization Measures Still Pending
• Oklahoma House Passes Psilocybin Decriminalization And Research Bill, Sending It To Senate
• Rhode Island Lawmakers File Psilocybin And Broader Drug Decriminalization Bills While Legal Marijuana Momentum Increases
• Utah Senate Approves Psychedelic and Mental Health Bill
• Drug companies are investing big in psychedelics, but can they engineer out the trip?
• Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline
• Demand grows for UK ministers to reclassify psilocybin for medical research
• Benzinga Expands Footprint into the Psychedelic Industry with the Launch of the Benzinga Psychedelic Advisory Council
• Dr. Bronner’s Partners With Pioneering Health Plan Administrator, Enthea, To Provide Psychedelic Therapy As Employee Healthcare Benefit
• Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations
• MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects
• It’s Time to Start Studying the Downside of Psychedelics
• MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program
• Core One Labs Announces Successful Proof-of-Concept for a Biosynthetic N-methyltryptamine (NMT)
• Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics
• Fireside Project manifests a $200K fund to improve access to careers in psychedelic health
• More People Are Microdosing for Mental Health. But Does It Work?
• Dr. Bronner’s, the Soap Company, Dips Into Psychedelics
• Small Pharma Inc.: World’s First Clinical Trial For DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
• Mycrodose Therapeutics Granted DEA and FDA Approval to Cultivate Psilocybin Mushrooms in the United States
• COMPASS Pathways Posts Wider Net Loss In Q4, Gives Update On Psilocybin Research
• Ethics in Psychedelics: Fireside Project’s Equity Initiative
• Awakn Files Patent For A New Class Of Entactogen-Like Molecules
• UK Set To Become Hub Of Psychedelic Research
• A Look at the Vine Ventures/MAPS Funding Structure
• Vine Ventures: Rethinking Venture Capital for a Novel Approach to Health & Wellness
• MAPS and Vine Ventures Pioneer Novel Regenerative Funding Structure to Infuse Psychedelic-Assisted Therapy Research and Access With Timely $70 Million
• Strengthening the European Psychedelic Ecosystem: Partnership Between Octarine Bio and Clerkenwell Health
• Group Ketamine Pilot; Therapist Training Platform’s Seed Round; Durable Response to PAT at 12 Month Follow up
• Peter Thiel-backed firm takes majority stake in a brain computer interface start-up
• Noetic Fund II Leads Series A Financing into CaaMTech Inc.
• Noetic Commits to Investing $6.95M into Seed Round for The Alexander Shulgin Research Institute for Psychedelic Drug Discovery and Development
• Noetic Launches Second Fund to Invest in Emergent Psychedelic Medicine Sector
• Beckley Psytech Raises £14m ($18.6m) to Advance Development of 5-MeO-DMT for Neuropsychiatric Diseases
• atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
• Mindset Pharma Highlights Psychedelics Insights Through COPE Program
• Cybin, Deepak Chopra Announce Partnership For Psychedelics Awareness And Education
• DEA Faces Challenge To Proposed Psychedelics Ban In Its Own Administrative Court
• Oklahoma Lawmakers Approve Psilocybin Decriminalization And Research Bill In Committee
• PSYC Executes Initial Investment into The Conscious Fund
• The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of
• Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders
• Lobe Sciences Announces Publication of PCT Patent Application for Its Combination Therapy for mTBI and PTSD
• Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD
• Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board
• Lobe Sciences Successfully Completes Proof-of-Concept of Proprietary Nasal
  Mist Device
• Oregon releases first draft rules for therapeutic psilocybin program
• The Mindful Metaverse; Intravenous Psilocin; MindState Design
• Microdose Psychedelics Presents a Molecular Masterclass: The LSD Conference
• Big Pharma In Psychedelics: Inside Mindset Pharma’s Deal With Otsuka
• Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility
• DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics Industry
• Are Psychedelics the Future of Pain Relief?
• A Y Combinator startup that’s creating a new class of psychedelics just raised $11.5 million from big Silicon Valley investors
• Utah Lawmakers Vote To Study Benefits Of Psychedelics In Treating Mental Health Disorders
• Health Canada Denying Psilocybin Access to Healthcare Professionals
• Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca’s Active Ingredient
• Seattle Doctor Files DEA Petition To Reschedule Psilocybin For Medical Use
• Can microdosing psychedelics boost mental health? Here’s what the evidence suggests.
• Leafy Tunnel announces the first closing of its medical cannabis and psychedelics fund
• How AI could unlock the medical potential of psychedelics
• Oregon Lawmakers File Psilocybin Equity Bill As State Implements Legal Use Program
• Are Double-Blind Studies Holding Back Psychedelic Research?
• Congressman Blasts DEA Over Psychedelics Scheduling At Event With Former GOP Colleague
• Sensible policy on psychedelic drugs is growing more common
• Psychedelic therapy shows great promise. More states should legalise it
• Numinus Identified as a Licensed Psilocybin Supplier by Health Canada
• Psychedelics Today Launches Vital: 12-Month Immersive and Inclusive Psychedelic Certificate Training for Professionals
• The Promises and Perils of Psychedelic Health Care
• Colorado Activists File Revised Ballot Initiatives To Legalize Psilocybin And Establish ‘Healing Centers’
• Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014
• Oklahoma: GOP Lawmakers File Bills To Decriminalize Psilocybin
• Survey Finds Majority of Affected Americans Approve Psychedelics to Treat Anxiety, Depression, PTSD
• Training begins for psychedelic-assisted clinical trial
• $14.8 million for innovative mental health clinical trials
• New Coalition Seeks To Reschedule ‘Magic Mushrooms’ Under International Law
• DEA Moves to Add 5 Psychedelic Tryptamines to Schedule I
• Bipartisan Congressional Lawmakers Tell DEA To Allow Psilocybin Treatment For Terminal Patients
• Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent
• Rollups: The Emerging Magic Mushroom Monopoly
• A Psychedelic May Soon Go to the FDA for Approval to Treat Trauma
• Psygen Receives Dealer’s Licence from Health Canada
• Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
• Awakn Life Sciences Signs MOU with MAPS
• Two-thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
• British Psychedelic Drug Firm Eleusis Plans $450 Million SPAC Deal
• MindMed Enrolls First Participant in a Study of its Session Monitoring System
• Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program
• Numinus seeks Health Canada approval to start psychedelic product trial
• Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
• Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain
• PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
• Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
• atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
• Psychedelic beer served at intimate dinner parties helped an ancient empire in the Andes rule for centuries, study finds
• Top Federal Drug Official Says ‘Train Has Left The Station’ On Psychedelics As Reform Movement Spreads
• Sydney Researchers Awarded Over $2.2 Million By Australian Government To Study MDMA, Psilocybin
• PsyMed Ventures, our $25M fund to invest in psychedelic medicine & mental health tech
• Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA
• Psilocybin Services Would Be Legalized In Washington State Under New Bill
• New Filing Challenges Compass Pathways’ Infamous Patent on Synthetic Psilocybin
• Ketamine therapy swiftly reduces depression and suicidal thoughts
• Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder (TRYPF)
• Cybin Earns Notice Of Allowance For CYB004
• Entheon Biomedical Corp
• Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments
• MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
• Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom
• PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022
• DEA Should Allow Psilocybin Therapy For Terminally Ill, Says Congressmen Blumenauer, Seeks Lawmakers’ Support
• Mydecine Innovations: Further advancement of drugs derived from psychedelic compound psilocybin
• Ixtlan Bioscience Announces the Filing of New Patent for the Psilocybin Treatment of Alzheimer’s Disease and Brain Pathologies
• Crystallographic Discoveries Bring New Clarity to Pharmaceutical Psilocybin Polymorph Characterization
• Center to Study Psychedelics for Treatment of Depression, Anxiety, PTSD Launches at UT Austin’s Dell Med
• It’s Clearer Than Ever – The Active Compound in Ecstasy Can Safely Assist PTSD Therapy
• COMPASS Selected for Addition to NASDAQ Biotechnology Index
• Canada Allows Three Mental Health Patients to Access Psilocybin Therapy
• Discovery Behavioral Health Acquires Awakenings KC Clinical Neuroscience Institute
• Douglas Pharmaceuticals announces positive top-line results from Phase 2 trial of R-107 in subjects with Treatment Resistant Depression
• New Delivery Option for Ketamine
• TGA blocks use of MDMA, magic mushrooms trials for mental health
• Mydecine Innovations Group (OTCMKTS: MYCOF) To Launch Phase 2/3 Smoking Cessation Study Using Psilocybin
• Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program
• Re-emerging Magic Molecules: The Medicalization of Psychedelics in the United States
• Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
• Ketamine Infusions Becoming a Popular Anxiety Treatment Option in Chicago
• There’s a psilocybin and Kambo medicinal retreat coming to Detroit in March 2022
• More patients granted psilocybin exemption by federal government
• New York Lawmaker Files Bill To Legalize Medical Psilocybin Treatments, With Focus On First Responders And Veterans
• Seattle’s UW Medicine to study effects of psilocybin on stressed-out healthcare workers
• “The New Cannabis” – the present and future of psilocybin as a medical treatment in Canada
• Psychedelic substance Ibogaine to be tested for potential as an addiction treatment
• PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian Glaucoma Society to Their Scientific Advisory Board to Enhance Ongoing DMT Studies to Treat Glaucoma
• Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
• COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
• HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S. for Research Purposes
• Numinus Wellness ends fiscal 2021 with $1.5M in revenue after Mindspace Wellbeing acquisition
• Ketamine-assisted therapy is having a moment in Utah
• Consuming Psilocybin Mushrooms Help Alleviate Depression in People
• Virginia Lawmakers Tout Benefits Of Psychedelics As Activists Prepare Push For Statewide Reform
• MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System
• Nue Life announces donations to Multidisciplinary Association for Psychedelic Studies and Ketamine Research Foundation
• Nextleaf Solutions Ltd (OTCMKTS: OILFF) Receives a Controlled Substance Dealers License
• Algernon Pharmaceuticals appoints two consultants for its DMT stroke clinical program; completes manufacturing supply for trials
• United Nations Panel Rejects International Kratom Ban
• Evidence Inconclusive for Ketamine as Bipolar Depression Treatment
• Ketamine One adds Seattle location to its expanding US clinical network
• Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder
• Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures
• Are psychedelics superior for treating mental illness? Potentially, yes
• Psilocybin therapy of psychiatric disorders is not hampered by hERG potassium channel- mediated cardiotoxicity
• Fibromyalgia Management Solutions Now Available In Chicago
• BetterLife Pharma Inc. (OTCMKTS: BETRF) Provides Preliminary Behavioural Animal Pharmacology Data For TD-0184A
• GH Research Reports Positive Phase 2 Study Results For TRD
• Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference on December 6, 2021
• Nova Mentis to Present at the H.C. Wainwright Psychedelics Conference
• MDMA and psilocybin could be removed the TGA’s list of prohibited drugs
• Ketamine One Teams Up With Cognetivity Neurosciences To Study PTSD, Depression
• DMT: A Trip To Get Away From Depression?
• Creso Pharma subsidiary secures upgrade to its Controlled Drugs and Substances Dealer’s Licence
• Colorado panel finds ketamine can be used safely in field, recommends more training and monitoring
• People ‘microdosing’ on psychedelics to improve wellbeing during pandemic
• Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America’s First Integrative Mental Health Clinic Network
• Curated Mental Health to launch nationwide offices to increase access to psychedelic assisted psychotherapy
• Ketamine Retreat Center, Floresta, Announces New Year’s Retreat for December 30th – January 2nd at YO1 Health Resort in the Catskill Mountains, NY
• Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
• Sunstone Therapies Launches to Accelerate and Scale Psychedelic Therapy in the Medical Setting
• MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin
• Psychedelic Telemedicine Has Arrived. What Could Possibly Go Wrong?
• Psychedelics, Virtual Reality, & Experiential Medicine Part I: Predictive Processing
• As ketamine clinics emerge to treat mental illness, so does debate about safety and regulations
• PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
• MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation
• COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences
• Love Pharma’s Acquisition Will Offer Exclusive Partnership and License with World Renowned University to Conduct Landmark Psilocybin Study
• Psychedelics can change humanity for the better. It’s time to unlock their power
• Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans
• Ketamine One Provides Second Update on Management Cease Trade Order
• Braxia Scientific is making a scientific case for psychedelic medicine
• Jamaican magic mushroom breaks into Canadian market
• atai Life Sciences increases its ownership position in COMPASS Pathways
• UBCO study finds LSD, magic mushrooms microdosing helps improve mental health
• PsyBio Therapeutics is developing psychoactive compounds which could be a mental health game changer
• Entheon Biomedical: Data and DMT among the keys to creating safe and effective treatments for patients battling addiction
• Monash secures more than $13m in NHMRC Ideas Grants in neuroscience and mental research
• Mindset Pharma is pursuing breakthroughs in the psychedelics field with the help of “hard science”
• Is Psychedelic Research Funding Starting to Shift?
• Psychedelic psilocybin cuts cravings and boosts key brain functions in rat models of alcohol use disorder
• Biomind Labs advancing its DMT therapeutic to treat depression in Brazil-based Phase II study
• iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products
• Ketamine as an Antidepressant With Dr. Lisa Monteggia
• Research on psychedelics could lead to new treatments for mental illness
• The Rise of Psychedelic Retreats
• Revive Therapeutics Inc. (OTCMKTS: RVVTF) Signs Psilocybin Research Partnership Agreement With PharmaTher Holdings Ltd. (OTCMKTS: PHRRF)
• HAVN Life Successfully Exports Naturally Derived Psilocybin From Its Jamaica Facility Into Canada
• On the verge of legality: This is how founders discover the business of LSD shops and therapies
• PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
• Ketamine Wellness Centers, Veterans Affairs Community Care Network Partner to Provide Free Treatments to Veterans With PTSD
• Former GOP Texas Governor Promotes Psychedelics Research For Veterans At Event With Leading Experts
• Ketamine nasal spray for depression restricted to trained providers
• Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
• Pasithea Therapeutics Brings New Depression Treatments To London
• Psychedelic Companies Keenly Aware Of Creating Therapies As Healthcare Reimbursement Possibility Looms
• Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University
• COMPASS Pathways granted fifth US patent for crystalline psilocybin
• Inside The Race To Create A Two-Hour Psychedelic Therapy Experience
• MDMA and psychotherapy in combination could be used to treat alcoholism
• 1st Trial of Anesthetic Ketamine for Depression in Parkinson’s Wins $2M
• H.C. Wainwright Stick to Their Buy Rating for ATAI Life Sciences
• HAVN Life Successfully Exports Psilocybin from its Jamaica Facility into Canada
• Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments
• PA Psilocybin Bill Could Make The State A Frontrunner In Psychedelic Research, Aiding Vets & First Responders
• Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
• Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form
• Psilocybin Can Reduce Cravings In Alcohol Dependent Rats, And Now We Know Why
• Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders
• Orange County lawmakers want state, federal agencies to consider regs for kratom
• Delic Launches Industry’s First Family Support & Education Program at Ketamine Wellness Centers (KWC) Nationwide For Patient Community/
• Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods
• Psychedelic companies say Compass study result validates industry’s hope to find alternative treatments for mental health
• Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint
• Way2Grow (W2G) Biopharma Corp. Receives Health Canada Approval Notice for Construction of a Controlled Substances Dealer’s Licence Level 8 Psychedelic Secure Environ and Psilocybin Production Campus
• Nextleaf Provides Update on Status of Health Canada Application for Psychedelics Dealer’s Licence
• Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression (TPIA)
• MindMed Lists on NEO to Become World’s First Psychedelic Pharmaceutical Company to Go Public
• MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
• Ocrevus Benefited RRMS Patients Who Responded Poorly to DMTs
• Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK
• Ketamine One says wholly-owned subsidiary, IRP Health recently opened two veteran-focused and multidisciplinary clinics in Comox Valley and Ottawa
• Allied Corp Progresses Towards Clinical Phase I Trial for Psilonex™ RX Psilocybin Pharma Drug
• Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory
• Warning of ‘wild west’ in depression treatment as UK clinics offer ketamine
• Big Tech’s Psychedelics Grift
• DEA Quadruples Psilocybin Manufacturing for Research in Final 2021 Production Quotas
• Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce
• Will We Turn to Psychedelics for Mental Health Treatment After the Pandemic?
• Psilocybin clears biggest depression test yet, but Compass stock falls amid chatter about adverse events, durability
• Psilocybin therapy boosts cognitive and neural flexibility in depressed patients, study finds
• Australian Therapists to Be Given Psilocybin to Better Understand Their Patients
• Canada Reaches Psychedelic Milestone with First Legal Group Psilocybin Therapy Session
• Forgotten Psychedelics: What Is 2C-B?
• Filament Health Announces FDA Authorization of Clinical Trial with First-ever Direct Psilocin Administration and First-ever Psychedelic Botanical Drug Candidates
• Why drugs should be not only decriminalised, but fully legalised
• Is it Possible to Create an Ethical Psychedelics Company?
• Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder
• Pasithea Therapeutics Corp’s (NASDAQ: KTTA) Subsidiary Pasithea Clinics Administers First Intravenous Ketamine Therapy
• Greek Australian at the helm of Monash University’s push for the use of psychedelics to tackle mental health
• Bill on magic mushrooms aims to make Pa. a national leader in psychedelic research
• Psychedelics Help Heal Childhood Trauma, Study Finds
• First legal Psilocybin Mushroom group therapy treatment for nine end-of life-patients
• NanoAlchemie Files Patent on Groundbreaking Drug Delivery System for Psychedelics and Medicinal Mushrooms
• Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’
• Klarisana Expands to Longmont, Bringing Psychedelic Therapies to Northern Colorado Communities
• Psychedelic therapy research is on the horizon for Texas veterans with PTSD
• Single Infusion of Ketamine Rapidly Reduces Suicidal Thoughts
• Biomind Labs to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
• New drug development targets could fill a need in treatment for depression
• Denver City Council Considers Expanding Psilocybin Decriminalization
• PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
• Psychedelics Celebrates First Business Conference
• Will Smith reveals ayahuasca use during split from Jada Pinkett Smith in memoir
• EMA Grants Nova Mentis Life Sciences Corp’s Fragile X Syndrome Psilocybin Drug Orphan Drug Status
• Delic Acquires Arizona-Based Ketamine Wellness Centers For US$10 Million
• Herbal Supplement Giant To Enter THC, Psychedelics Industries, Seeking To Become First Household Brand To Do So
• Compass Pathways’ Phase IIb psilocybin trial shows reduced depression symptoms
• Study: Mixing CBD With Ketamine Might Be Great For Depression
• PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics
• Algernon Pharmaceuticals reports positive pre-clinical data on DMT candidate to treat stroke
• IBN (InvestorBrandNetwork) and PsychedelicNewsWire to Further Collaborate with Microdose Psychedelic Insights for the Upcoming Wonderland Miami Conference
• Levitee Labs announces acquisition of addiction clinics, pharmacies for expanding its pain and addiction relief services
• Key Legal Considerations Relating to Ketamine Behavioral Health Platforms
• DMT Drug Co. Price Rockets Over 15%
• Mycrodose and Nova Mentis to launch Phase 2 neuroinflammatory-focused trial using psychedelics
• Cava Healthcare Announces Sale of Its Patented “Use of Psychedelics to Treat Dementia” Technology
• Italian Activists Turn In More Than Half A Million Signatures For Marijuana And Psilocybin Referendum
• Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program
• Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program
• Developments with Ketamine Psychotherapy Are Driving A Medical Revolution For Treating Mental Health Issues
• MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform
• IHL’s psilocybin treatment takes 2 steps forward, with a boost from the FDA and ethics approval to commence trials at Monash University
• Clearmind Signs Development and Supply Agreement to Produce its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
• Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials
• Pasithea starts ketamine therapy for patients with treatment resistant depression in UK
• Ibogaine Drug Development: Creating The Gold Standard For Addiction Treatment
• Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease
• Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds
• MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias
• Irwin Naturals sets up wholly-owned units to enter US, Canada recreational cannabis market and psychedelic mental health industry
• Delic Announces Partnership with GT Research
• Psychedelics Group Issues First Round Of Grants For Community-Based Entheogenic Education In DC
• MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program
• Seelos Therapeutics Presents a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
• Can Magic Mushrooms Help Treat Anxiety?
• Sweden Experimenting With Rats on LSD to Cure Depression, Addiction
• Cybin target raised at Oppenheimer after psilocybin data from Compass Pathways
• Specialty Pharmacists May Speed Time to MS Treatment
• Ketamine One says it intends to submit a draft registration statement for a proposed US IPO
• Delic Acquires Arizona-Based Ketamine Wellness Centers For US$10 Million
• Revive Therapeutics Ltd. (OTCMKTS: RVVTF) Included in Inaugural PSIL ETF launch and Offers Bucillamine Study Updates
• Agtech and KRTL Biotech Join Forces to Develop and Distribute Unique CBD and Psilocybin Products
• Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome
• Dr. Bronner’s Funds Psilocybin Legalization Effort in Connecticut
• How ketamine therapy helped this Canadian veteran
• Pervasip Corp. Asset KRTL Biotech Inc. Welcomes Agtech Global International Inc. to its Psilocybin Research Project in South Korea
• MindMed CMO to Chair Digital Biomarkers Summit
• Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT
• Thailand govt says that special permission needed to sell drinks containing kratom
• Alcami, PharmaTher Enter Manufacturing Agreement
• European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders
• Canadian entrepreneur gifts $5 million to help create psychedelic research centre for mental health
• Hopkins Scores $4 Million From NIH To Study Psilocybin As Tool To Quit Smoking
• Clinic offering ketamine for mental health therapy planned for Vancouver
• Peak Human Announces Launch of the Psychedelic Frontiers Virtual Summit
• Significant Increase in Production of Cannabis and Psychedelics for Research Proposed by the DEA for 2022 – What You Need to Know Now
• Three Toronto centres offering psychedelic-assisted therapy
• Global Roundup: Newly-Launched AION Forms Startup in Israel
• Psychedelic Unicorn Compass Pathways Receives New Patent Approval
• Fourth Massachusetts City Approves Psychedelics Reform As Movement Grows
• Knowde Group Inc.™ launches in the UK with the addition of Chief Medical Officer, Project Lead, and announces strategic partnership with QNTM Labs
• PharmaDrug Commences Trading on the OTCQB Market in the United States
• Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
• Awakn Life Sciences Bristol Clinic Receives Care Quality Commission Approval to Begin Treatments in the UK’s First Medical Psychedelic Clinic
• Origin Therapeutics to be a Silver Sponsor for Major Psychedelics Conference, Wonderland: Miami
• Canadian Biotech Company Pursuing Psychedelics with Unique Compound
• Studies on ayahuasca in Ribeirão Preto project USP as a reference in research on hallucinogens
• Boris Johnson considers calls from Tory MP to legalise magic mushroom drug
• After Cannabis, Maltese People Want To Legalise Mushrooms Next
• Historic: Federal Agency Awards Grant For Psychedelics Research, First Time In 50 years
• Levitee Labs announces partnership with Adracare to provide psychedelic digital care for addiction and mental health treatment
• Pharmocann teams with Shamir Institute on magic mushrooms
• Diamond Therapeutics Announces First Patient Dosed in Health Canada Approved Trial Evaluating Low-Dose Psilocybin
• Expert: MDMA Is Very Likely to Be FDA-Approved for PTSD by the End of 2023
• The club is bumping: Recreational ketamine use on the rise, Langone study finds
• Creso Pharma’s subsidiary Halucenex’s key psychedelic ingredient passes crucial testing and is one step closer to phase two clinical trials
• PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products
• Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies
• First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial
• Emyria passes MDMA analogue development milestone with Eurofins to lead extensive compound screening program
• This Company Just Extended its Reach into the United Kingdom by Opening its First Ketamine Therapy Clinic
• Another California City Approves Measure to Decriminalize Psychedelic Substances
• UAB researcher granted federal funding for psilocybin and smoking study
• Bank Of America Cancels Account Of Marijuana And Psychedelics Research Institute Registered With DEA
• Psychedelic use might be ‘beneficial’ for heart health
• Oakland Psychedelics Activists Launch Initiative To Legalize Community-Based Sales With Support From City Council
• DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone
• Mindset Pharma Expands Benchmarking Data for First-Generation Psychedelics Through the COPE Program with InterVivo Solutions
• A Strategy for Rescheduling Psilocybin
• Guy Goodwin joins COMPASS Pathways as Chief Medical Officer
• Emotional Intelligence Ventures Announces Their Qualification of a Regulation A+ Public Stock Offering